Spironolactone

Chemical formula: C₂₄H₃₂O₄S  Molecular mass: 416.573 g/mol  PubChem compound: 5833

Therapeutic indications

Spironolactone is indicated for:

Hypokalemia

Population group: only adults (18 years old or older)

Hypokalemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Edema, generalized

Population group: only adults (18 years old or older)

Generalised oedema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Congestive heart failure

Population group: only adults (18 years old or older)

Congestive heart failure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nephrotic syndrome

Population group: only adults (18 years old or older)

Nephrotic syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hepatic cirrhosis

Population group: only adults (18 years old or older)

Cirrhosis of liver

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Severe heart failure (New York Heart Association Class III-IV)

Population group: only adults (18 years old or older)

at least one of
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Malignant ascites

Population group: only adults (18 years old or older)

Malignant ascites

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Primary aldosteronism

Population group: only adults (18 years old or older)

Primary hyperaldosteronism

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Spironolactone is contraindicated in the following cases:

Acute renal insufficiency

Acute renal insufficiency

Anuria

Anuria

Addison's disease

Addison's disease

Hyperkalaemia

Hyperkalemia

Eplerenone

Eplerenone

Moderate to severe renal impairment

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

at least one of



Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: ALDACTONE Film-coated tablets
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈